- LIVE QUOTES
- LEARN
- HELP
More from Webull
Our Partners
Nasdaq
Wall Street JournalEN
E
ERAS
Erasca, Inc.
12.54
0.15+1.21%After Hours: 12.43 -0.11 -0.91%17:06 02/20 EST
OPEN/PREV CLOSE12.38/12.39
TODAY RANGE12.16-12.76
VOL2.41M
MARKET CAP3.84B
52 WEEK RANGE1.010-13.28
AVG VOL (3M)5.31M
% TURNOVER0.79%
TURNOVER--
P/E (TTM)-27.8296
% RANGE4.84%
EPS(TTM)-0.4506
P/E(FORWARD)-28.5000
P/B10.23
BVPS1.226
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP3.14B
SHARES OUTSTANDING306.21M
NEXT EARNINGS03/18-03/23
FREE FLOAT250.34M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·4d ago
Will Early ERAS-0015 Signals at Guggenheim Summit Reshape Erasca's (ERAS) RAS Pipeline Narrative?
Simply Wall St·5d ago
Assessing Erasca (ERAS) Valuation After Early Clinical Signals And Strong Share Price Momentum
Simply Wall St·02/06 13:06
Erasca (ERAS) Is Up 15.2% After Upsized Offering Extends Cash Runway For RAS/MAPK Pipeline
Simply Wall St·02/03 14:21
Assessing Erasca (ERAS) Valuation After A Powerful Share Price Run And High Price To Book Premium
Reuters·01/30 14:04
Erasca CFO and CBO David M. Chacko Reports Acquisition of Common Shares
TipRanks·01/29 22:25
Erasca extends cash runway after upsized public offering
Simply Wall St·01/29 17:19
Does Erasca’s US$225 Million Equity Raise and ERAS-0015 Data Change The Bull Case For ERAS?
TipRanks·01/27 12:22
Erasca price target raised to $12 from $5 at Guggenheim
Reuters·01/27 11:11
ERASCA INC <ERAS.O>: GUGGENHEIM RAISES TARGET PRICE TO $12 FROM $5
TipRanks·01/27 10:45
Erasca (ERAS) Has a New Rating from Mizuho Securities
TipRanks·01/27 10:10
Erasca assumed with an Outperform at Mizuho
Reuters·01/27 07:49
U.S. RESEARCH ROUNDUP-AMETEK, Stryker, Zimmer Biomet Holdings
Benzinga·01/26 13:05
Revolution Medicines, Erasca And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Same Industry
Name/Symbol
Change%
Price